View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 26, 2021updated 11 Jul 2022 2:16pm

Initiator Pharma obtains approval to begin trial for pain-reducing effects

The Phase I study will use IP2015 in healthy male subjects challenged with pain-inducing ingredient (capsaicin).

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and the local Ethics Committee have approved Initiator Pharma’s clinical trial application (CTA) for Phase I trial to evaluate pain-reducing effects.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The planned Phase I study in the new IPTN2021 clinical programme will be carried out together with MAC Clinical Research, UK.

It will use the drug substance, IP2015, in healthy male subjects challenged with pain-inducing ingredient (capsaicin).

The clinical programme is targeting an orphan drug indication being developed to treat severe neuropathic pain, trigeminal neuralgia.

It is based on the company’s IPED2015 API, which has already demonstrated safety and tolerability in clinical trials and showed efficacy for erectile dysfunction.

A monoamine reuptake inhibitor, IP2015 specially inhibits dopamine and serotonin reuptake.

It has also been used as the active pharmaceutical ingredient in the IPED2015 programme, which is now undergoing a Phase IIb trial in 120 patients to treat organic erectile dysfunction.

Initiator Pharma CEO Claus Elsborg Olesen said: “I’m very pleased we have received the approval to start this exploratory Phase I trial for our new IPTN2021 programme targeting the orphan drug indication trigeminal neuralgia.

“The study will provide important pain-related efficacy, biomarker and safety information to support the planned clinical development of our drug substance IP2015 into relevant pain indications.

“We hope to be able to start dosing the first patients early next year. Our intention is to follow up this trial with a Phase II trial, including trigeminal neuralgia patients.”

The company expects subject enrolment and dosing to begin early next year.

In March 2020, Initiator Pharma reported favourable data from the Phase IIa study that assessed IPED2015 in severe erectile dysfunction patients.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena